The Patent Finder

Gradalis, Inc.

Also on record
Records under this name other than the patents Gradalis, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 17 patents it holds.

Back to Gradalis, Inc.

PatentTitleStatus Expires Confidence
US 9,290,763Construction of bifunctional short hairpin RNA
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,556,431ShRNA molecules and methods of use thereof
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,683,237Multiple Targeted Rnai for the Treatment of Cancers
Formerly held
Lapsed on the fee record
Ended Jun 20, 2025 · Medium confidence
Lapsed on the fee recordEnded Jun 20, 2025Medium confidence
US 8,460,908Polypeptides Having Colanic Acid-Degrading Activity
Lapsed on the fee record
Ended Jun 11, 2025 · High confidence
Lapsed on the fee recordEnded Jun 11, 2025High confidence
US 9,562,023Dipeptide mimics, libraries combining two dipeptide mimics with a third group, and methods for production thereof
Lapsed on the fee record
Ended Feb 7, 2025 · From the USPTO record
Lapsed on the fee recordEnded Feb 7, 2025From the USPTO record
US 8,361,983Novel Therapeutic RNA Interference Technology Targeted to the PDX-1 Oncogene in PDX-1 Expressing Neuroendocrine Tumors
Lapsed on the fee record
Ended Jan 29, 2021 · High confidence
Lapsed on the fee recordEnded Jan 29, 2021High confidence
US 8,333,988Targeted delivery using tissue-specific peptidomimetic ligands
Lapsed on the fee record
Ended Dec 18, 2020 · From the USPTO record
Lapsed on the fee recordEnded Dec 18, 2020From the USPTO record
US 9,273,300Methods and compositions for modulating sialic acid production and treating hereditary inclusion body myopathy
Formerly held
Lapsed on the fee record
Ended Mar 1, 2020 · From the USPTO record
Lapsed on the fee recordEnded Mar 1, 2020From the USPTO record
US 9,133,459Novel Therapeutic RNA Interference Technology Targeted to the PDX-1 Oncogene in PDX-1 Expressing Neuroendocrine Tumors
Lapsed on the fee record
Ended Sep 15, 2019 · High confidence
Lapsed on the fee recordEnded Sep 15, 2019High confidence
US 8,969,068Processes for the Preparation of Highly Pure Plasmid Compositions by Enzymatic Digestion of Colanic Acid
Lapsed on the fee record
Ended Mar 3, 2019 · High confidence
Lapsed on the fee recordEnded Mar 3, 2019High confidence
10 of 15 patents shown.
Pro members see all 15.
Pro members: see all 15 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited